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Abstract: Introduction: Cognitive enhancers (CEs), also known as “smart drugs”, “study aids” or
“nootropics” are a cause of concern. Recent research studies investigated the use of CEs being
taken as study aids by university students. This manuscript provides an overview of popular
CEs, focusing on a range of drugs/substances (e.g., prescription CEs including amphetamine salt
mixtures, methylphenidate, modafinil and piracetam; and non-prescription CEs including caffeine,
cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and vinpocetine) that have emerged as
being misused. The diverted non-prescription use of these molecules and the related potential for
dependence and/or addiction is being reported. It has been demonstrated that healthy students (i.e.,
those without any diagnosed mental disorders) are increasingly using drugs such as methylphenidate,
a mixture of dextroamphetamine/amphetamine, and modafinil, for the purpose of increasing their
alertness, concentration or memory. Aim: To investigate the level of knowledge, perception and
impact of the use of a range of CEs within Higher Education Institutions. Methodology: A systematic
review was conducted in adherence with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. Whilst 1400 studies were identified within this study through a
variety of electronic databases (e.g., 520 through PubMed, 490 through Science Direct and 390 through
Scopus), 48 papers were deemed relevant and were included in this review. Results: The most popular
molecules identified here included the stimulant CEs, e.g., methylphenidate, modafinil, amphetamine
salt mixtures and caffeine-related compounds; stimulant CEs’ intake was more prevalent among
males than females; drugs were largely obtained from friends and family, as well as via the Internet.
It is therefore suggested that CEs are increasingly being used among healthy individuals, mainly
students without any diagnosed cognitive disorders, to increase their alertness, concentration, or
memory, in the belief that these CEs will improve their performance during examinations or when
studying. The impact of stimulant CEs may include tolerance, dependence and/or somatic (e.g.,
cardiovascular; neurological) complications. Discussion: The availability of CEs for non-medical
indications in different countries is influenced by a range of factors including legal, social and ethical
factors. Considering the risk factors and motivations that encourage university students to use CE
drugs, it is essential to raise awareness about CE-related harms, counteract myths regarding “safe”
CE use and address cognitive enhancement in an early stage during education as a preventative
public health measure.
Keywords: neuroenhancement; cognitive enhancement; drug abuse; university students; study
drugs; non-medical drug use; smart drugs
1. Introduction
Cognitive enhancement is defined as an “amplification or extension of core capacity
of the mind by improving the internal and external information processing systems” [1].
Cognitive enhancement can be achieved in two ways, e.g., “pharmacologically”, by taking
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cognitive enhancer (CE) drugs/substances; or “non-pharmacologically”, by maintaining
a healthy lifestyle, which includes being physically, mentally and socially active; eating
a healthy, balanced diet; drinking alcohol only in moderation; and maintaining good
sleep habits [2]. CEs, also known as “smart drugs” or “nootropics”, are a heterogeneous
group of chemical substances that are used to improve cognitive function [3], particularly
memory, alertness, attention, learning performance, creativity and motivation [4]. CEs
are typically being obtained, and at times by healthy individuals [5,6], on prescription,
over-the-counter, online, or through other sources such as family or friends [7]. The clinical
impact of CEs’ ingestion can be significant, with these molecules being able to affect
various neurotransmitter pathways in the brain, including the cholinergic, dopaminergic,
noradrenergic and serotonergic pathways [8]. Whilst their mechanism of action is not fully
understood [3], most popular CEs (e.g., methylphenidate, modafinil and amphetamine
salt mixtures) are stimulants [9]. Methylphenidate increases the levels of noradrenaline
(NA) and dopamine (DA) in both the prefrontal cortex and the cortical/subcortical regions,
and this effect may be associated with levels of improved attention in Attention Deficit
Hyperactivity Disorder (ADHD) [10]. Conversely, with modafinil—a medicine being used
to treat narcolepsy—stimulant actions are associated with an impact on NA, glutamate
(NMDA or N-methyl-D-aspartate) and DA [11]. In particular, modafinil increases DA levels
in the caudate and nucleus accumbens (Nac), whilst blocking DA transporters in a healthy
individual’s brain [12]. Out of these molecules, modafinil may be better tolerated, inducing
less adverse drug reactions, whilst not being associated with a high risk of dependence [13].
The amphetamine salt mixtures (e.g., in the branded product Adderall) block the re-uptake
of both NA and DA into the pre-synaptic neuron, and increase their release as well from
the pre-synaptic neuron, hence increasing their concentrations in the synaptic cleft [14].
Indeed, since the 1940s, both modafinil and amphetamine (e.g., “go pills”) CE cate-
gories have been the subject of military research, to help soldiers stay alert whilst attenuat-
ing the effects of sleep deprivation [15,16]. However, these drugs are increasingly being
used by healthy individuals, including students and night shift workers, to improve their
cognitive and motivational functions [17]. Associations between CEs and drugs in sports
have been investigated [18]. CEs and drugs in sports share many aspects with respect to
“enhancement” and “doping”. The former may be more socially acceptable, whilst the
latter is considered illegal and is heavily monitored by organisations such as The World
Anti-Doping Agency (WADA). The use of freely available CEs, such as caffeinated products
and vitamins, have been investigated in athletes as “gateway” and “predictor” of physical
enhancers use. The non-monitored CEs were found to be highly used among athletes with
or without physical enhancer use [19]. Studies also showed that users of erogonomic aids
such as caffeine may favour doping due to “biased reasoning patterns” [19].
It is important to note that students using CEs do not only aim to achieve a cognitive
enhancement, but also a motivational enhancement and an overflow of energy. They may
use a combination of CEs as well as alcohol, and/or recreational sedatives, in an attempt
to achieve a good quality sleep, reduce nervousness and improve overall performance in
exams and study-related assessments [20,21].
The lifetime prevalence rate of prescribed CEs’ intake for non-medical reasons, as
a self-attempt to increase cognitive performances, among university students in the UK
and Ireland has been estimated to be around 10% [22]. However, these levels of intake
may be underestimated [23] and the trend has attracted a considerable interest [22], re-
lating to its social, ethical and legal implications [24–26]. Whilst most studies have fo-
cused on the prevalence of a limited range of a few CEs (e.g., amphetamine salt mixtures,
methylphenidate and modafinil), focusing on intake by students in Higher Education
Institutions (HEIs), a study by Napoletano et al. (2020) identified a total of 142 unique
CEs. These molecules were then sub-grouped into 10 categories, according to recently
proposed classifications [27] including: prescribed drugs, plants/herbs/products, psychos-
timulants; image- and performance-enhancing drugs (IPEDs), miscellaneous, GABAergic
(gamma- aminobutyric acid-ergic) drugs, phenethylamines, cannabimimetics, tryptamine
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derivatives, and piperazine derivatives. In parallel with the continuous emergence of
new/novel psychoactive substances (NPS), which has enriched the repertoire of illicit drug
use [28], this manuscript aims to provide an updated overview of the use of CEs among
university students.
2. Methods
The current systematic literature review was performed in adherence with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines [29], to estimate CEs’ prevalence of intake; and assess knowledge, awareness and
impact of CEs’ use among university students.
2.1. Literature Search (Inclusion and Exclusion Criteria)
The focus here was on quantitative and qualitative studies relating to CEs’ use among
University students: The literature search was performed using a range of key word
strings, e.g., cognitive enhancers AND neuroenhancement, prescription drug misuse OR
prescription drug abuse among healthy individuals AND enhancement. In particular, the
search strategy was conducted from three databases Scopus, PubMed and Science direct.
Finally, a manual search was also carried out using Google Scholar in order to ensure none
of the key articles and studies were missed.
Inclusion criteria were quantitative (surveys) and qualitative (interviews) studies
having been carried out among healthy students aged 18 years and older in HEIs. Articles
were included if they related to a range of nine CEs (prescription CEs including am-
phetamine salt mixtures, methylphenidate, modafinil and piracetam; and non-prescription
CEs including caffeine, cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and
vinpocetine), which were selected here because of their popularity among university stu-
dents [4,7,22,26,30]. Studies written in English, from the year 2000 (i.e., from around
the time when NPS started to emerge in drug scenarios) to 2020 were included in the
study search. Regional/world drug reports (e.g., from the European Monitoring Centre
for Drugs and Drug Addiction/EMCDDA and the United Nations Office for Drug and
Crime/UNODC) were included here as well. Conversely, studies focussing on underage
children, on preclinical experiments or students with medical diagnoses using the selected
drugs/substances for medical reasons were excluded from the study. Non-English articles
were also excluded.
2.2. Quality Assessment
Based on the inclusion criteria, the selected articles were appraised for quality using
PRISMA checklists [29]. Search results were exported to Mendeley, a free reference manager
and academic social network. This tool was used to determine the structure of the index
study methodology [29].
3. Results
3.1. Summary of the Literature Search
The literature search identified a total of 1400 studies here (e.g., 520 through PubMed,
490 through Science Direct and 390 through Scopus) (Figure 1). Forty-eight studies were
excluded as they were duplicates, 1294 studies were screened and were excluded based on
their title and abstract, 10 did not meet the inclusion criteria, and 48 were deemed relevant
and were included in this review (Table 1).
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Table 1. Summary of the literature review focusing on Cognitive Enhancer (CE) drug(s)/substance(s) being considered for the study (e.g., methylphenidate, amphetamine, modafinil and
piracetam, caffeine pills, guarana, cobalamin (vitamin B12), vinpocetine and pyridoxine (vitamin B6).














Out of 506 participants,
45.5% (n = 230) reported
that they had used a range
of CE drugs in the
previous 12 months for the
purpose of study. Male
usage was reported as
being more than two and a
half times higher than
female usage.
The motivational factors
behind CE use were
investigated with greater
understanding of the factors
influencing their use.
Universities need to develop a
greater awareness of the
prevalence of CE use amongst
their students and consider






- 1865 participants. Online survey.
Out of 1865 respondents,
4.2% had used CEs in the
previous 12 months, and
the prevalence among Law
students reached 14.3%.
The most commonly used
smart drug was
methylphenidate. The
drug was mostly obtained
through a friend.
The limitation was the
questionnaire itself. It is
possible that there was a
memory bias and omission of
response, underestimating the
prevalence found. However,
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Online survey. 17% reported having usedsmart drugs previously.
The limitation of this study
was that it was open to all UK
full-time undergraduate
students, although the
majority of the participants
were from Russell Group
universities. However, they
did not collect additional data
on discipline or university and,
therefore, cannot be sure how
representative the sample is
for the UK university
population as a whole or the
population at the host
university. This means that
factors such as
competitiveness cannot be
extracted from the data.





All users took Modafinil,
with some also having
tried Dextroam-
phetamine/amphetamine
and Ritalin for the purpose
of study. By recruiting
both users and non-users,
all non-users were found
to be female.
All interviewees reported
improving academic study as





were judged to be highly
desirable in the context of time
constraints and fatigue when
approaching exams and
deadlines.
Brain Sci. 2021, 11, 355 6 of 44
Table 1. Cont.












students in the one
University of
Medical Sciences
students from 1st to
5th year.
Paper survey.
Some 44 (17.6%) of the
respondents answered that
they had used CEs at least
once in their life, to
increase concentration.
There was a significant
relationship between CE
use and the age of






had used, stress level and
CE use (p < 0.05).
Sample collection was one of
the main limitations. For
example, the female sample
was larger than the male
sample. Students entered the
study without prior notice of
it, which means that a factor
may play a role, as well as
memory bias, especially when
students are being asked to
record non-pharmaceutical
use. Finally, it is
recommended that a study
should be conducted in all
universities of Iran and their
results compared. Therefore,
although it is obvious that the
use of these drugs for
increasing cognition was
investigated more among
student populations, it is not
possible to generalise to other
populations.
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Reference Country Prescription CE Non-Prescription CE Study Sample Methodology Used Results/LifetimePrevalence of CE Notes/Limitations
[34] Pakistan Methylphenidate -
A cross-sectional
study was conducted












admitted the use of
Methylphenidate to
improve concentration.
Peer pressure was found to
be a major factor in its
misuse.
The study determined the
prevalence of non-therapeutic
use of methylphenidate as
well as ascertaining any
benefits, side effects, and other
factors associated with this use.
This is a cross-sectional study
and, apart from a chi-square
test, no other statistical
analysis could be performed.
The study only includes two
cities in Pakistan and must be
expanded to include other
regions as well, especially the
regions labelled as high risk
for drug misuse. This study
does not extensively explore
the reasons for a participant
opting for drug abuse,
regardless of academic
performance or environment.
[35] Brazil Methylphenidate -
Simple random
sample of students of
the Universidad
Federal de Minas
Gerais (n = 438),
invited to answer an
online questionnaire
about the use of
methylphenidate
Online survey.
Out of 378 students
included, 5.8% (n = 22)
reported using
methylphenidate for CE; of
them, 41% (9/22) in the 4
weeks prior to the survey.
The study estimates the
prevalence of, and factors
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Approximately 8.7% of the
students reported that they
used CE to improve their
academic performance
during exam time.
The study investigated the
prevalence of the non-medical
use of methylphenidate and
knowledge of this drug among
Undergraduate Medical











Approximately 5% to 30%
of students reported the
use of CE.
The study has certain
limitations. Firstly, for
confidentiality reasons, they
did not ask participants about
their own history of using CEs.
This precluded them from
knowing when participants
were truly referring to a friend
in their narratives, or when
they were following the
interviewer’s instructions to
mask their own illicit activities.
Second, they did not directly
question participants on how
they knew about the effects of
CEs, as this was an
unexpected line of inquiry.
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433 medical students. Paper survey.
Approximately 74.7% of
the students said they have
used CE to improve
cognitive functions. The
remaining students were
aware of concerns about
safety and side effects.
The study explored the use
and attitudes toward the use
of CE in Italian Medical
students. Only one university
was involved; therefore, the
generalizability of their
findings to the whole Italian
student population is limited.

















use. The mean age of the
stimulant drug users was
24.6 ± 4.8 years. The main
initiating factor was to
improve concentration (29
persons; 59.2%).
The study was to evaluate the
current situation of stimulant
use among Medical students
and residents of Babol
University of Medical Sciences.
The survey was conducted in
class before the lecture started,
so the students may have been
in a rush to finish the
questionnaires.
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use. Two data sets
from the male and
female Global Drug
Survey (GDS).
The Global Drug Survey
(GDS) is the largest study
on CEs drugs that has ever
been conducted. Across
both years, there were
more male than female
respondents.
According to responses
from both years, the main
source of supply for CE
drugs participants was the
circle of friends (47.8%).
One in ten indicated that
the Internet was their main
source (11.8%).
Family members with a
prescription (6.1%) and
physicians (3.8%) were less
common sources for
stimulant drugs used for
CEs. Overall, 4.9% and
13.7% of the global sample
reported the use of CE
drugs to improve
performance at work or
while studying.
Several limitations were
considered: The first two and
most important limitations of
the study are the self-selection
of GDS survey participants
and the use of self-reported
data. Since the sample is
self-selected and the substance
use for CE drugs consists of
self-reported data, the actual
extent of CE drugs in the
participating countries is not
accurately known.




A third limitation is that the
impact of recall bias or
deliberate misreporting on
results must be considered.
Finally, due to the anonymous
web survey instrument, the
same individual might have
completed the GDS2015
multiple times. However, <1%
of the sample provided
identical response sets across
demographics and key
variables used in these
analyses.
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- 1136 Australianstudents. Online survey.
6.5% reported that they
used CE to improve
academic performance.
The study found that the
prevalence of non-medical
prescription stimulant use, to
improve academic
performance, is low among
university students in
Australia. The cross-sectional
design means that it is not
possible to infer causal
relationships between the use
of prescription stimulants and
other factors. The use of
self-reporting measures may
have introduced recall and
social desirability biases.
[42] Austria - Caffeine pills 2284 students. Paper survey.
14.9% of participants
reported the use of
Caffeine pills.
(I) To investigate whether





increases the PN prevalence
estimate (framing effect),
(II) To investigate whether the
health-related risk attitude is
increased in students who
use PN.
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- 642 students. Online survey.
6.32% of individuals
reported lifetime use of
one or more prescription
CE drugs, listed for the
purposes of study-related
enhancement.
Even though this study
provides some insights into
the CE drug use that occurs at
Australian universities, there
are some limitations to
consider. Results should be






were also oversampled. As a
result, the distribution of the
students in the current study
may not be an accurate
representation of the entire
student population at
Australian universities. The
number of illicit CEs drug
users was also so low that
statistical analyses were
deemed inappropriate for this
group. Therefore, caution
should be exercised in
interpreting the results, given
the constraints of the sample.




students that use CE drugs,
particularly contextualised
regarding coping.
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Caffeine All Level 1 and Level4 M. Pharm.
Paper survey.
Convenience sample.
The response rates were
89.3% (Level 1) and 89.0%
(Level 4) with 48.0% of
respondents reporting they







The study could be done for
other Schools, such as other
healthcare disciplines.
However, the opinions were
captured at one point in time,
data were self-reported, and
the findings are not
generalisable. Perhaps, if the
study had been conducted
immediately before the written
examinations, prevalence of
CE use would have been
higher. Manually distributing
paper-based questionnaires to
students in a compulsory class
and an online distribution
would enhance the response
rate. Other ways to maximise
the response rate included
having a relatively short
questionnaire with questions
largely as closed questions.
Educational workshops could
further explore ethical issues.
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- 591 Medical students. Online survey.




and about 1 in 4 used illicit
drugs, mostly for
recreational purposes, with
cannabis being the most
frequently used.
To analyse the prevalence of
lifetime and current use of
illicit drugs among Medical
students worldwide.
Considering that CE use




needed to elucidate the
prevalence and the motivation











Response rate was 88.6%
(442/499).
Prevalence rate of CE was
6.6% in the university
environment sampled
There were no significant
differences in student
motivation and learning
strategies between users of
CE and non-users.
To investigate what factors
explain the decision to use CEs
among tertiary students in
New Zealand, using the
Theory of Planed Behaviour.
This research supports the
notion that the decision to use
CEs is not just an autonomous
choice that occurs in isolation.
Attitudes on the ethical and
social acceptability of CE use
were more likely to drive the
decision to use CEs.
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seems to differentiate users
from non-users of PCEs.




use PCEs among university
students.










There are few limitations in
this study. The survey was
self-administered, and the
questionnaire was conducted
in class before the lecture
started, so the students may
have been in a rush to finish it.
The questionnaire was not






or misusing it for reasons not
related to their ADHD.
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thought that it is a good
choice to use CEs.
This study was conducted to




on the neural mechanisms
underlying response. Not able
to disentangle neural
activation in response to
successful vs. failed
inhibitions in the present
study due to the modest
number of no-go trials. The
small number of inhibition
trials (i.e., no-go trials) also
limited the functional
relevance of the behavioural
results, albeit MPH and
modafinil significantly






- 38 students. Interview. n= 5 had used CEs.
CEs users reported higher
levels of stress and lower
levels of ability to cope than
the sample average.
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Year 1 to year 4.












Eighty-six per cent of the
175 participants, both
males and females, at
Zayed University, Dubai
consumed caffeinated
beverages with an average
intake of 249.7 ± 235.9 mg.
The intake among the 150
caffeine consumers varied
from 4.2 mg/day to
932.2 mg/day.
The study was to determine
the prevalence of caffeinated
beverage consumption among
university students and the
perceived benefits. In addition
to the estimation of daily
caffeine consumption, the
study was undertaken in one
university only.
In the UAE, the limited studies
that were done regarding this











- n = 521. Online survey.
Approximately 11% used
CE without prescription,
42% had a prescription.
The reason for the misuse




prescription stimulants and to
summarise the literature with






misuse. Lack of understanding
in variability according to
dose level and individual
variability is a clear limitation




Brain Sci. 2021, 11, 355 18 of 44
Table 1. Cont.















reported the use of CE,
mainly to increase
academic performances
and to stay awake during
exam preparations.
To estimate the prevalence of
psychostimulant use in the
French medical community
and their motives. Lack of
direct information on the
period of stimulant use. It was
a choice to keep the
questionnaire short to
maximize the response rate.
This limit was partially
addressed by the age at the
first psychostimulant use,


















reported that they had
used CE in their lifetime.
To analyse the use of cognitive
enhancers among medical
students in Lithuania, to
determine the reasons for
usage and evaluate the
contributing factors, such as
sociodemographic
characteristics, stress levels,
sleep quality and knowing
somebody who has used a
neuro-enhancing drug.
Students participated in the
study without any previous
knowledge about it, which
means that a surprise factor
may have played a role and
memories could be biased.
Brain Sci. 2021, 11, 355 19 of 44
Table 1. Cont.












Caffeine pills Interview n = 35Survey n = 113
Online survey and
Interview
From 113 respondents in
the survey, 24 (21%)
reported having tried CEs.
Most of participants
turned to CEs to enhance
their concentration for the
purpose of study and time
management.
Future research needs to take
into account the great variety
of drugs/substances that







- 1572 students. Online survey.
No response was reported
on the use of Modafinil
and Rivastigmine. 52
students reported the use
of methylphenidate. 36%
had used Beta Blockers at




the student population in the
Netherlands. Women, for
example, were oversampled.
In addition, the sample was
not equally distributed for
different universities, as well
as not distributed being in line
with the absolute difference in
number of students of the 14
Dutch Government supported
universities.
[57] Iran Methylphenidate Alcohol 16,000 medicalstudents. Paper survey.
The prevalence of
prescription drug misuse,
alcohol use in the previous
year, and every illicit
substance use was 4.9%,
6.9%, and 2.9%,
respectively.
There is limited information
about illicit drug use and
associated factors in hookah
smokers in Iran. So, the aim of
this study was to assess the
status of illicit drug use and
associated factors among
hookah smokers of Khalil
Abad city in 2015.
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Reference Country Prescription CE Non-Prescription CE Study Sample Methodology Used Results/LifetimePrevalence of CE Notes/Limitations
[21] Switzerland Methylphenidate,Modafinil -
Students at three
Swiss universities
were invited by email











toward PCE. The response rate
for the present survey was
10%. The study sample may
not have been necessarily
representative of all Swiss
students. Although all
students from UniBas and
ETHZ (ETH Zürich
University) were invited, only
5000 of a total of 26,000
students who were currently
enrolled at University of
Zürich (UZH), who had
previously agreed to be









- 877 students in 104universities.







Only 2% reported that they
have used CE.
Results from the convenience
sample survey may be biased,
due to participants’
self-selection. They only used
an online survey, which was
considered too costly and
unfeasible due to
access barriers.
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n = 908, Bath Spa
n = 462, Oxford
Brookes n = 203,
Chester n = 883,
Plymouth n = 167);
Wales (Swansea
n = 398); and the
Republic of Northern
Ireland (Ulster






Some 5% reported that
they had regular use of CE,
and 25% used CE
occasionally, and
70% never.
The study could be carried out
at other schools, such as other
in healthcare disciplines.
However, the opinions were
captured at one point in time,
data were self-reported, and
the findings are not
generalisable.
Perhaps if the study had been
conducted immediately before
the written examinations,
prevalence of CE use would
have been higher. Manually
distributing paper-based
questionnaires to students in a
compulsory class and an
online distribution would
enhance the response rate.
Other ways to maximise the
response rate included having
a relatively short
questionnaire with questions







- 1765 students. Online and papersurvey.
4.7% had used CE for the
purpose of studying.
The findings from this survey
can lead to a better
understanding of why some
students are already using CE
and can also add to the
discussion on social norms
and values in the context of
legalizing or prohibiting
such products.
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Online survey sent to






(67.4%) declared to have
consumed at least one
cognitive enhancer in the
past 12 months. Twelve
students (8.6% of cognitive
enhancers users and 5.8%




motivations for licit (use inside
medical indication) and illicit
pharmaceutical neuroenhancer
consumption (tablet form) in a
non-selected French sample of
Medicine and Pharmacology
students. A prevalence of 5.8%
for smart drugs consumption
in Pharmacology and Medical
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- 4 years repeatedstudy. Online survey.
1 in 5 students reported














perceptual intelligence and a
standardized achievement test.
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- 18 participants. Interview.
Among all participants (n
= 18 = 100%), 77.8% (n =
14) had used illicit
stimulants (AMPH) and
38.9% (n = 8) prescription
stimulants (MPH). 22.2%
(n = 4) had used





reported. One of them is the
limited number of interviews:
Only 18 interviews were taken
into consideration. In spite of
the fact that the University
population was 36,000
registered students who had
the possibility to notice the
advertising placards of this
interview study throughout
the campus, only 30 students
contacted them, and only 22
were willing to participate.
Given CE prevalence rates of
3–20%, there should have been
a much higher number of
potential participants for this
study. They hypothesize that
the stigmatizing subject of this
study is the reason for the low
participation rate,
notwithstanding the fact that
anonymity was guaranteed
and that participants were
remunerated for their time
and effort with 30 Euros.
Brain Sci. 2021, 11, 355 25 of 44
Table 1. Cont.
Reference Country Prescription CE Non-Prescription CE Study Sample Methodology Used Results/LifetimePrevalence of CE Notes/Limitations











reported that they used CE
at least once in their
lifetime.
Given that students’ responses
are self-reported, and that
non-medically prescribed
stimulant use is illegal,
misreporting is a potential
concern in this survey.
However, the survey did not
distinguish between giving










- 213,633 tweets. Online survey.
Approximately 12.9%
tweets concerned the use
of Adderall for studying
purposes.
First, not every Adderall tweet
was related to actual use. For
example, they observed song
lyrics that impact these counts,
such as the two often quoted
lines “College hoes love
alcohol and popping Adderall”
and “I’ve been up for 3 days
. . . Adderall and red bull.” In
our sample, there were 4275
tweets that have the words
“college hoes love” and 894
that have the words “been up
for three 3 days”. These
numbers probably inflate the
number of matches for
“college”, “alcohol”, and “red
bull” above the number of
people tweeting about using
these substances.
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varied by sex (male 23.7%,
female 17.0%), field of






As a result of the study
findings, drug prevention
models need to be established














and 26.3% Respiratory the
students reported the use
of CE to enhance alertness
and improve academic
performance.
The incidence of psychosis or
withdrawal associated
depression is not known for
prescription drugs.
[67] Canada Methylphenidate,Modafinil Caffeine pills
647 Medical students
across all four years. Online survey.
Approximately 8% of the
Seniors report the use of
CE vs. 2% of Junior
students using CE for
cognitive enhancement.
It was carried out at a single
institution; however, we have
no reason to believe that the
results are not generalizable to
students studying elsewhere.
While self-selection may have
led to a positive response bias,
it is equally plausible that non
respondents did not wish to
disclose use of cognitive
enhancers.
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[68] UK Methylphenidate Caffeine pills 1614 students. Online survey.
Approximately 33% had
used drugs without
prescription of which 0.5%
used stimulants for a
studying reason. 6% used
caffeine pills.
The limitation in this study is
that the response rates are
quite low and also the study is








- 77 Undergraduatestudents. Paper survey.
Approximately 16%
reported they had taken
CE in the past.
The limitation in this study is
the question on CE use which
did not specify what exactly
the students took; their
behaviour risk is difficult to
assess and assumes that the
truly problematic behaviour is
to take CE drugs without
having a prescription.
[70] Iran Methylphenidate - Group of Medicalstudents Paper survey.
Approximately 8.7%
reported the use of
methylphenidate at least
once in their lifetime.




on their willingness to reply
truthfully to the survey.
Second, the sample in the
study was from one university,
thereby necessitating that
similar studies be conducted
in other medical schools for
comparison. Third, the study
did not explicitly address
duration or frequency of
methylphenidate use.
Therefore, it is unknown
whether non-prescription
users took methylphenidate
regularly or only occasionally.
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pupils from Vocational and




lifetime provenance for CE
use. 2.42% of pupils vs.
2.93% of students reported




were not able to refuse
participation in a discrete way.
At least in the student
population, in which
approximately 30% did not fill
in the questionnaires; it cannot
be excluded that stimulant use
is underreported since
especially students with
“negative behaviours” did not
fill in the questionnaires,






- 4580 students. Online survey.
Approximately 75.8%
reported that they have
used amphetamine
(Adderall) in the past year,
24.5% used
methylphenidate (Ritalin).
Sample consisted of students
from a single university, which
may limit the generalizability
of the results. However, the
prevalence rates of illicit use of
prescription stimulants in this
single institution study were
comparable to those found in
national surveys of college
students.
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- 9161 students. Paper survey.
Approximately 8.1%
reported lifetime use of CE,
5.4% reported past year
use of CE to increase
alertness and concentrate
better.
The 2001 College Alcohol
Survey (CAS) did not measure
legitimate medical use of
prescription stimulants or
diagnosis, so it was not
possible to assess how many
students with legitimate
prescriptions for stimulants
may have misused their own
or someone else’s stimulant
medication. As the data were
cross-sectional, inferences
about causality are limited and
they could not assess whether
certain factors preceded
initiation of non-medical use
of prescription stimulants.
Longitudinal data are needed
to further examine the
directionality of these
associations.
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- 150 students. Paper survey.
Approximately 35.3%
reported they had misused
Amphetamine once in
their lifetime, 10% abused
it monthly and 8% weekly.
Reports of stimulant use are
high in the research; it may be
that a relatively small sample
was not representative of
college students in general,
despite attempts to avoid
selection bias. A significant
proportion of students came
from Undergraduate
Psychology classes and these
students may differ from those
in other Majors. Alternatively,
it is possible that small,
competitive colleges attract
students who have been
exposed to stimulant use, or
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Figure 1. Cognitive enhancers’ intake by university students: Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Flow Diagram.
Table 1 shows the summary of findings from the literature review on the prevalence
of CEs among university students.
Nine studies were conducted in the UK (i.e., six survey studies, two interviews and one
mixed methods study). The remaining studies included survey studies that were conducted
in the USA (n = 8) and Iran (n = 4). In Australia, three surveys and one interview, in Canada,
two surveys and one focus group interview, in Germany, three surveys and one interview
were conducted. Three survey studies were carried out in each of the following countries:
Brazil, France, Italy and Switzerland. Two survey studies were carried out in each of the
following countries: Austria, Belgium, Greece, New Zeeland and the Netherlands; and one
survey study was carried out in each of the following countries: Hungary, Iceland, Ireland,
Lithuania, Pakistan, Portugal, South Africa and UAE. Finally, one mixed-methods study
was carried out in both Lithuania and the Netherlands. Participants were students from a
range of disciplines, including Medicine, Pharmacy, Engineering, Law, Computer Science,
Business, Education, Psychology and Social Sciences. The sample size of the different
studies ranged between 77 and 80,000 participants each.
An overview of the demographic variables, prevalence of use, technical knowledge
of CEs, motivations for use, source of CEs’ acquisition and positive/negative subjective
effects is summarised here.
1. Demographics’ variables
Males were here identified as the most typical CE
misusers [7,22,30,31,41,51,52,63,66,70,71,73–75], with some studies reporting a male:female
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ratio of 3:1 [54]. In contrast with this, a Welsh study reported that female representation was
slightly more than males [68].
2. Prevalence of CEs’ use
A growth of CEs’ intake over the past few years has been reported, including from
both high-ranking universities and highly competitive courses such as Medicine and
Pharmacy [41]. In the UK, findings showed that 33% of the participants used CEs which
were not prescribed to them for the purpose of study [68]. In a survey conducted among
UK and Ireland university students, it was found that the lifetime prevalence of the use of
modafinil, methylphenidate and amphetamine were, respectively, 6.2%, 5.9%, and 2% [22].
Conversely, the lifetime prevalence of CEs’ intake among University students in the US
was estimated to range between 5% and 43% [76]. More precisely, a meta-analysis from the
US estimated that the misuse of CEs among university students was 17% [75]. Compared
to the US, most British university students may be more cautious in using prescription
drugs as CEs [49].
A recent study in Brazil reported that, out of 1865 students from different academic
disciplines, 4.2% reported to having had used CEs in the last 12 months, with the most
popular molecule having been methylphenidate which was not associated with an ADHD
diagnosis. With respect to what is being described in less competitive study fields [77],
Medicine and Pharmacy have been identified as being both stressful and highly competitive
academic courses worldwide [44,45]. In this respect, a study that was conducted among
medical students in Iran (2000–2007) showed that methylphenidate users’ mean knowledge
score was higher than that of non-users (p = 0.008), with age (range 18–28 years), sex (male
92.5%) and 26% fourth school year having been positively correlated with knowledge score
(p < 0.05). Some 8.7% of participants had taken methylphenidate at least once in their
lifetime [70]. Similarly, a study carried out in Lithuania reported that the point prevalence
of CEs (modafinil, methylphenidate and amphetamine) among medical students was
8.1% [77].
Finally, caffeine use as a CE has grown in popularity worldwide [78]. A study in the
UAE assessed the prevalence and perceived benefits of caffeinated beverage consumption
among university students [51]. More than 98.5% of the study participants were shown to
be caffeine consumers, with 31% having reported being addicted to caffeine; heavy caffeine
consumption was significantly associated with heart problems [51].
Despite the global popularity of the non-prescription caffeine, most research articles
report the use of prescription CEs among university students. Therefore, the true prevalence
of prescription vs. non-prescription CEs among university students is not fully understood
and, hence, more research is needed.
3.2. CEs’ Knowledge and Reported Positive/Negative Effects
University students may be attracted by stimulant drugs for several reasons, e.g., to
increase awake time, enhance cognitive performance, improve professional and academic
achievement [41], but also to help with socialising and getting high [79]. Indeed, the main
motivations for misusing methylphenidate may relate to improving concentration (65.2%),
helping with studying (59.8%) and increasing wakefulness (47.5%) [73]. Other studies have
associated methylphenidate misuse with the need to help with concentration, stay alert,
have more energy and improve self-confidence levels [17,34,70]. A 2019 UK qualitative
study with Biomedical Science undergraduate students examined their understanding of
the risks of non-prescribed drugs, and particularly modafinil, misuse. Drivers of use were
related to university pressures and desires to increase productivity; the customisation of
the sleep–wake cycle was described as a key benefit of ‘study drug’ use [32].
Increasing the levels of cognitive performance may indeed potentially allow students
to study for more hours, and/or increase working memory performance [80]. According to
Greely et al. (2008), modafinil may be chosen as a CE because of its high online accessibility
and availability. Conversely, whilst studies in the UK suggested that CE drugs such as
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modafinil can enhance thinking skills [81], over-confidence was reported as one of the CE’s
side effects, together with a high risk of dependence [2].
The popularity of caffeine and related products as CEs may be related to the need to
boost energy, stay awake, improve mood, increase concentration and socialise [51]. In the
UAE, the mean level of knowledge about caffeine was described as less than 33%. Younger
participants (p = 0.008) and those who worked in healthcare and education (p < 0.001) were
significantly more knowledgeable about its negative effects, including anxiety, insomnia,
tachycardia, irritability and muscle tremors [51]. A recent systematic review focussing
on the effects of the caffeine-containing plant Paullinia cupana (“guarana”) on cognition
in young, healthy adults found improved levels in both reaction time and accuracy per-
formance [82]. Guarana has also been described to improve memory performance and
increase alertness levels [83]. Long-term use of high dose of guarana can, however, result
in a series of adverse effects, including irritability, palpitation and anxiety [2,84].
Despite the legal restrictions that control the possession and supply of controlled CEs,
students often obtain them due to their desired pharmacological effects. Table 2 summarises
the desired effects of CEs, their neuro-modulatory effects and their legal classification.
Mixtures of CE substances/drugs used by healthy students to improve cognition is
on the rise and is being considered as a type of “academic doping” [85]. Poly-CE use
has been documented in previous studies [86]. In Switzerland, users reported ingesting
methylphenidate in addition to other CEs. Others reported using both modafinil in addi-
tion to Alzheimer’s disease drugs. Others ingested antidepressants in combination with
Parkinson’s disease drugs [86]. Studies have shown that methylphenidate users were more
likely to use illicit substances as well e.g., marijuana and ecstasy (MDMA or 3,4-methylene
dioxymethamphetamine) as compared to other prescription CE users [9].
Poly-CE use with psychostimulant and other effects offers both synergistic and addi-
tive effects based on used substances, hence potentially combining cognitive effects with
wakefulness; emotional and/or motivational effects; mood-, performance-, and executive
functioning-enhancing and euphoric effects [87,88], with risks to health that may range
from mild to serious risks including dependence, tolerance and neurological, psychological
and cardiovascular disorders, with a risk of overdose potentially leading to death.
The 2015 Western Australian Stimulant Regulatory Scheme showed that students may
use CE to cope with study-related stress [89]. They also found that CE users are also regular
illicit psychostimulant users, yet the relationship between CE and other psychostimulant
such as MDMA (ecstasy) co-use/consumption is to be determined [90].
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Table 2. Studies summarising Cognitive Enhancers (CEs)’ legal classification, desired effects and neuro-modulatory mechanisms.
Drug/Substance Brand Name Misuse of DrugsRegulation (2001) (UK)
Misuse of Drugs Act
1971 (UK) Currently Recommended Clinical Use and Neuro-Modulatory Mechanism
Amphetamine salts Adderall Schedule 2 Class B
Amphetamines are a class of pharmaceuticals that include Adderall,
dextroamphetamine, and lisdexapmhetamine (L-lysine-d-amphetamine) [91].
These drugs were developed to treat attention deficit hyperactivity disorder
(ADHD) in adults and children [4]. These molecules are classified as Schedule
II according to the Misuse of Drugs Regulation (2001) and Class B according to
the Misuse of Drugs Act 1971, due to their high abuse potential. Even though
the risk of developing dependence on these drugs is believed to be low for
individuals taking them for ADHD, the Schedule II classification indicates that
there is a high potential for abuse and severe dependence [4]. These drugs
were also demonstrated to improve episodic memory, working memory, and
some aspects of attention in general population [92]. The therapeutic effect of
both amphetamine and methylphenidate in ADHD is consistent with the
finding of the abnormalities in the catecholamine system in individuals with
ADHD [93,94].
Caffeine Genius Caffeine Over-the counter (OTC) -
The usage of caffeine is increasing worldwide [95]. The underlying
motivations are mainly memory and concentration enhancement and physical
performance improvement. Coffee and caffeine-containing products affect the
central nervous system, with their locomotor activity stimulation and
anxiogenic-like effects [78]. Caffeine also impacts on other neurotransmitters,
including dopamine, noradrenaline, serotonin, glutamate, acetylcholine and
gamma-aminobutyric acid [96]. Caffeine consumption is very prevalent among
the UK [97] and UAE [51] population. Healthy consumption needs to be
promoted [51]. Although caffeine is also a stimulant, it is not illegal to use
without a prescription [66].
Cyanocobalamin
(vitamin B12) Athlete OTC -
It may help patients on long-term medications and those with neurological
disorders [98]. Cognitive performance can be improved, and the risk of brain
atrophy reduced, by Vitamin B12 [99].
Guarana (Paullinia
cupana) N-R-G OTC -
Paullinia cupana is a plant native to the Amazon basin which is especially
common in Brazil [100]. A review study on the effect of Guarana among
healthy individuals reported an improvement in reaction time and accuracy of
performance at cognitive tasks [82]. Guarana seeds are popular worldwide for
their cognitive, stimulant and behavioural effects [82].
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Drug/Substance Brand Name Misuse of DrugsRegulation (2001) (UK)
Misuse of Drugs Act
1971 (UK) Currently Recommended Clinical Use and Neuro-Modulatory Mechanism
Methylphenidate Ritalin Schedule 2 Class B
It is a stimulant drug used to treat ADHD and narcolepsy. It has been
controlled as Schedule II according to the Misuse of Drugs Regulation (2001)
and Class B according to the Misuse of Drugs Act 1971 due to its high abuse
potential. Volkow and colleagues (2004) showed the effects of methylphenidate
on motivation, which can affect academic performance whilst increasing
cognitive ability and improving students’ self-rated interest in a relatively dull
mathematical task. A study reported that methylphenidate has one of the
highest prescriptions rates, associated with an abundance of websites offering
to sell and supply the drug without a prescription to UK users [30]. University
students might be attracted to methylphenidate because of its alleged increase
in attention and focusing levels [101]. Among university students, the
self-reported misusing rates were from 1.5 to 31% depending on the different
surveys considered, with the most nationally (German white males, affiliated
with a formally organised fraternity) representative study estimating an annual
illicit methylphenidate usage of about 4% [101].
Modafinil Provigil Prescription-only-medicine(POM) -
Wakefulness-promoting agents such as modafinil and armodafinil are
stimulant drugs which are used in the treatment of narcolepsy and shift
workers sleep disorders [30]. The mechanism of action of modafinil is poorly
explained in the literature. It has been reported that modafinil affects
GABAergic and dopaminergic pathways in the prefrontal cortex and has
effects on neurotransmitter systems (e.g., noradrenaline and dopamine) [80].
Modafinil is praised for its ability to improve reaction time, logical reasoning
and problem solving [77].
Piracetam Nootropil POM -
Compounds from the racetam family include piracetam, oxiracetam, etc [102].
Piracetam belongs to the nootropic drugs’ group which includes the brain cell
metabolism and energy enhancement [103]. Although Piracetam is officially
recognized as a nootropic, its enhancing effects in the healthy individual’s
brain are moderate [54,104]. The racetam molecules are being used across a
range of brain disorders, including Alzheimer’s disease, narcolepsy, ADHD,
Parkinson’s disease and brain aging [105,106].
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Drug/Substance Brand Name Misuse of DrugsRegulation (2001) (UK)
Misuse of Drugs Act
1971 (UK) Currently Recommended Clinical Use and Neuro-Modulatory Mechanism
Pyridoxine
(vitamin B6) Nestrex OTC -
Pyridoxine, one of the most common forms of Vitamin B6 [107], is said to
significantly improve verbal memory and executive function [108]. It can aid in
the synthesis of neurotransmitters and amino acids. Some of these
neurotransmitters are norepinephrine, serotonin, GABA and dopamine [108].
There is no evidence that Vitamin B6 short-term use (e.g., for 5–12 weeks)
improves cognitive function or mood [109]. More evidence is needed to
determine whether Vitamin B6 supplements might improve cognition in
healthy people.
Vinpocetine
(Vinca minor) Cavinton OTC -
Is an alkaloid of the periwinkle plant (Vinca minor) [110], which has been
shown to exert a brain neuroprotective effect by a combined action on brain
metabolism, cerebral circulation and rheological properties of the blood. This
may boost the cerebral metabolism thus enhancing both oxygen and glucose
utilization whilst consequently improving cerebral functions and providing
protection even in conditions of hypoxia and ischaemia [111]. It is commonly
used as a nootropic that promotes memory formation [106].
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3.3. Sources of CEs’ Acquisition
Sources of CE acquisition may relate to friends and family [7,59]. Students diagnosed
with ADHD, but not taking their methylphenidate medication regularly, have been reported
as the main source for fellow students [4]. In another study, 75.5% of methylphenidate was
identified as having been purchased from friends at a university campus whilst 64.3% of
modafinil was obtained online [22]. Accessing the web for drug acquisition activities is a
reason for concern [30], with young people (18–25 years old) being at high risk because
there is no way to know what the actual ingredients of the drugs/substances are in those
products [30], they are extensive users of the Internet [112]; it was found that over a
third of the websites selling modafinil specifically recommended use of the drug to aid
studying [30].
4. Discussion
The current systematic review provided an in-depth and updated understanding on
CEs’ prevalence of use; levels of knowledge; and their impact on HEI university students,
which is clearly a critical public health issue. The past few years have seen increasing levels
of concern about the use of pharmaceutical cognitive enhancement among university stu-
dents worldwide, with the lifetime prevalence of CEs misuse among these subjects ranging
from 6% to 20%, depending on the study subject [67]. Of particular concern, however,
is CE’s use in Health Sciences/ Biomedical students [34,36,38,39,45,48,54,57,63,67,70,71].
Most data initially emerged from the United States [61,75,113], eventually followed by
reports from the United Kingdom [22], Australia [46,50]; and Europe, namely from
France [53,60], and Italy [38,69].
The most popular prescription CEs among the selected ones in this study were
modafinil, methylphenidate and amphetamine salt mixtures [71], with methylphenidate
being the most popular among students [9]. Conversely, the most popular freely available
CE was Caffeine [78]. Although not confirmed by some studies [113,114], males were iden-
tified here as more likely to use CE drugs than females [31,52,63,71,75,77]. Some studies
also showed that, despite that the number of female participants was higher than their
male counterparts, the rate of CE use was much higher than in female students [77].
Although no differences between genders in favouring methylphenidate as the most
popular CE or in the preferential choice of any CE were recorded, there were gender
differences in motivation for use [33]. Female students’ motivation for CE use were to
increase concentration, memory, alertness and academic performance, and because “friends
use it”. In contrast, male students’ motivations for CE use were mainly to increase study
time and experiment [33].
In general, with regard to illicit substance use, Dr Adam Winstock (CEO of the Global
drug Survey) pointed out the gender differences, explaining it as possibly resulting from
societal stigma, shame and cultural expectations around women taking drugs. Additional
factors that influence women’s decisions in using drugs include pregnancy and motherhood.
Economic status and the lower rate of criminal activity amongst women also reduce female
drug use and exposure to illicit drugs as compared to males [115].
Indeed, several social factors have been identified here to influence CEs’ use practices
among university students [56]. These included: peer-pressure, competition, performance
demands and prior drug use [85], but also recreation [79].
The availability of CEs for non-medical indications in the different countries is af-
fected by a range of factors, including legal, social, and ethical factors [33,40,116]. Indeed,
some CEs are being openly made available online [30,117], where they are marketed as
“smart drugs”, “study drugs”, “plant food”, “research chemicals” and “designer drugs”
as well [30,112]. The unregulated online access, and especially so for modafinil and
methylphenidate, is likely to be associated with an increase in CEs’ non-medical use and
subsequent harm [30]. Indeed, high levels of modafinil may have reportedly been sold and
shipped to students at high-ranking/top UK universities, mostly during the examination
period [118]. Conversely, as CEs’ legal alternative to either prescribing or illicit drugs of
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abuse, guarana was found here to be popular, with affordable online prices encouraging
young users/students to buy greater quantities in order to receive discounts and free
shipping [30,119].
Sahakian et al. (2008) opened a debate on the positive impact on improving cognitive
functions, suggesting that benefits of CEs should be maximised, and their harm min-
imised [25]. In some studies, CE drugs have been shown to moderately enhance cognitive
performance in healthy individuals [120]. Accordingly, CE tools including pharmacolog-
ical cognitive enhancement could improve the quality of life of both busy workers and
exhausted students to extend their work/academic productivity levels [121], hence bene-
fitting both the individual and society [25]. There have been extensive reports focussing
on CEs’ intake to aid concentration and memory among healthy individuals, including
students, academics, shift workers, and even chess players to improve their cognitive
performance [122]. A study by Smith and Farah (2011a) suggested that the effects of both
methylphenidate and amphetamine salt mixtures on cognitive performances in healthy par-
ticipants showed positively consistent effects in learning, but especially so in delayed recall
and recognition testing, pointing to an effect on memory consolidation [4]. An additional
study by Schelle et al. (2015) showed a positive effect of methylphenidate on memory and
planning performance in healthy individuals. However, others have suggested that evi-
dence regarding the clinical benefits of CEs in healthy individuals is still inconclusive [123].
A 2010 systematic review and meta-analysis of published randomised controlled trials
of the effect of both modafinil and methylphenidate in healthy individuals showed that
the anticipated effects of these two agents as cognitive enhancers exceeded their actual
effect [80]. Hence, it has been suggested that the ability of amphetamine-type substance
mixtures to enhance academic performance among students could be attributed to their
effect on energy, confidence and motivation levels rather than to a direct effect on cognitive
performances [124]. In fact, individuals may be biased in predicting their own performance,
e.g., they either underestimate or overestimate their academic competence [125]. Moreover,
cognitive improvement seems to vary considerably from one agent to another, and Smith
et al. (2011) reported that one third of studies from past literature reviews showed null
results. One could then argue that there are more unpublished studies in the literature with
null results, due to publication bias favouring positive results [4].
On the other hand, use of stimulant CEs may be associated with negative academic per-
formances in terms of the euphoric state induced, with abnormal mood elation preventing
the student from spending enough time in preparation for an exam [17,57]. Furthermore,
methylphenidate is reported to present with a dependence potential [126], and modafinil de-
pendence cases have been identified as well [127]. It is also worth noting the amphetamine-
type substance-related dependence; withdrawal; and psychosis issues [28]. Untoward
effects relating to the index CE may indeed influence students’ choices, with them being
keen to consider modafinil as opposed to methylphenidate and amphetamine salt mixtures.
Indeed, Steward and Pickersgill (2019) found that all their CE users had ingested modafinil,
with only some also having tried methylphenidate and amphetamine salt mixtures for
the purpose of study. In fact, students described how the use of methylphenidate and
amphetamine salt mixtures could result in dependence and hence these were approached
more cautiously [32]. Overall, however, the use of methylphenidate has significantly in-
creased, with its consumption, in defined daily doses, having increased to approximately
2.4 billion worldwide [35]. In the UK, both methylphenidate and amphetamine compounds
are Class B controlled drugs [128]. This means they can be provided via prescription, but
the maximum quantity issued should not exceed 30 days (unless justified by the prescriber)
and a personal import/export licence is required to transport the drug in or out of the UK
if the amount exceeds a 3-month supply [30]. Modafinil is a prescription-only medicine in
the UK, but it is not controlled under the Misuse of Drugs Act 1971 or subject to scheduling
under the Misuse of Drugs Regulations 2001; hence, it is illegal to supply it without a
prescription, but it is not illegal to possess the drug for personal use [128]. To cope with
these restrictions, CEs’ selling websites provide discreet packaging; offer free reshipment if
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the package is seized; and encourage third-party, difficult to track, payment methods [30].
This outcome suggests running campaigns that mitigate harm and raise awareness among
students who use CE drugs. Finally, although caffeine is also a stimulant, its use is not asso-
ciated with either acquisition, affordability, availability, or legality issues [42,66]. However,
with caffeine high-dosage intake a range of medical and psychiatric effects can be observed,
most typically including anxiety, panic attacks, sleeping disorders and cardiovascular
issues [129].
A Cochrane review found no evidence that short-term intake of vitamins B6 and B12
supplements improve cognitive function or mood. The review did find some evidence that
daily vitamin B6 and B12 supplements can affect biochemical indices of vitamin B6 and B12
status in healthy individuals, but these changes had no overall impact on cognition [107].
According to the review of the literature, the drugs selected were chosen based on their
popularity among healthy university students, but the drugs most used among students
were (modafinil, methylphenidate and Adderall) and, in terms of substances, caffeine was
the most popular among university students. However, a study by Carlier, J (2019) reported
that methylphenidate is one of the most popular CEs and several analogues appeared on
the drug market during the last years. However, little or no scientific data on these new
analogues are available.
As sports organisations such as WADA are overviewing and prohibiting the use
of physical enhancers, no such control exists in schools and universities. Therefore, in
order to decrease the long-term deleterious effects of CEs in individuals who use them,
government-level interventions are urgently required.
A harm reduction programme is also recommended to reduce the negative, legal and
societal impact of substance use [125]. The programme should consider supporting individ-
uals with problematic substance use and their families with compassion and appropriate
advice and interventions, whilst safeguarding their dignity [125]. These findings suggest
the importance of raising awareness of the harms of CE use, provide accurate knowledge,
counteract myths regarding “safe” CE use and address cognitive enhancement in an early
stage during education as a preventative public health measure.
5. Limitations
There are a few limitations that were considered in this manuscript. The first limitation
is related here to the sole focus on English language studies having been included in the
search; future studies should consider further languages. The second limitation relates to
the methods used by the different studies, typically involving self-reporting surveys which
could have introduced biases. Finally, the current study focused only on undergraduate
students; however, postgraduate students, academic staff, and remaining workers should
be considered by future studies.
6. Conclusions
A number of students worldwide may be willing to consider CEs’ ingestion to im-
prove their academic performances. The attitude of university students about CEs and
their possible benefits is, however, based on anecdotal, and arguably biased, information
obtained from the media, the web, and friends [130]. Overall, it seems from this review
that the topic is not being sufficiently covered in the curriculum of modern universities.
Conversely, this issue should be discussed, as an inter-professional or inter-disciplinary
learning opportunity, from a public health perspective [7,44]. CEs’ use may arguably be
reduced if students’ levels of awareness were raised, emphasising that CEs’ intake may
pose a risk to safety, and especially so in vulnerable individuals [31]. Indeed, impacts
of CE drugs’ intake may include tolerance, dependence, withdrawal, cardiovascular and
neurological disorders with a related risk of death due to overdose [28,117,131]. The imple-
mentation of a harm reduction campaign, in order to bring the overall consumption down,
has been proposed as well [41,91].
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Finally, Shaw (2014) suggested that one of the most fascinating issues in the emerging
field of neuroethics is pharmaceutical cognitive enhancement. Medical debate [21,132] has
largely focused on the CEs’ potential to help those who are cognitively impaired. Hence, it
is here suggested that CEs’ use by university students, seems to raise the issue of “cosmetic”
neuropsychopharmacology [133,134].
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